Skip to NavigationSkip to content

Diabetes drug, originally developed for cats, approved for human use

Published on 24/01/23 at 09:56am

TheracosBio has announced that the first oral SGLT2 inhibitor, bexaflilozin, has been approved by the FDA for the treatment of adult patients with type 2 diabetes. The drug was originally indicated for cats with diabetes.

The once-daily treatment is recommended for adult patients with type 2 diabetes but is not indicated for those with type 1 diabetes or in diabetic ketoacidosis, however it can also be used for patients with stage 3 chronic kidney disease (CKD).

The approval follows 23 clinical trials, assessing the drug in over 5,000 patients with type 2 diabetes. The phase 3 trials showed significant HbA1c and fasting glucose reductions by the 24th week when used as a monotherapy, in combination with metformin, or as an additional treatment for those already being treated with sulfonylureas, metformin, insulin and DPP-4 inhibitors.

Mason Freeman, MD, of Massachusetts General Hospital in Boston, US, commented: “As a class of drugs, SGLT2 inhibitors have shown tremendous benefit in treating adults with type 2 diabetes. Being involved in all of the clinical trials for Brenzavvy, I am greatly impressed with the efficacy of the drug in reducing blood glucose levels, and I believe it is an important addition to the SGLT2 inhibitor class of drugs.”

 

Betsy Goodfellow


Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches